Articles related to TYPE 2 DIABETES

Because this GLP-1 agonist is known to reduce food intake, physicians have been prescribing tirzepatide off-label for weight loss for years. But unlike other drugs in its class, tirzepatide targets GLP-1 and GIP receptors.

The potential link between insulin resistance and bipolar disorder is causing a “paradigm shift in psychiatry,” remarked Dr. Cynthia Calkinan, associate professor of psychiatry at Dalhousie University in Halifax, Nova Scotia, Canada.

A new study published in Annals of Internal Medicine looks at the link between cardiovascular disease among adults with type 2 diabetes, which might be more prevalent than previously thought. This study compares cardiovascular outcomes in patients taking first line metformin vs. SGLT-2 inhibitors, based on claims data over a 7-year period. SGLT-2 inhibitor use was associated with lower rates of hospitalization for heart failure and all cause mortality. Rates for MI and stroke were similar for the two treatments.

Mounjaro (tirzepatide) is a first-in-class, once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single molecule. It enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. The FDA approval of Mounjaro as an adjunct therapy to diet and exercise for adults with type 2 diabetes was based on clinical trials where treatment with Mounjaro resulted in statistically significant reduction in both A1c and weight vs. semaglutide, insulin degludec, and insulin glargine.

Lilly Pharmaceutical’s Mounjaro (tirzepatide) is a once-weekly injection that promotes weight loss by mimicking the effects of incretins. This combination of a GLP-1 and a glucose-dependent insulinotropic polypeptide (GIP) yields weigh loss results comparable to surgical options.

Among adults aged 35 years or older with a body mass index (BMI) of 25 kg/m2, the prevalence of diabetes in Asian, Black, and Hispanic Americans was significantly higher than that in White Americans. Using screening thresholds specific to race and ethnicity has the potential to reduce disparities in diabetes diagnosis.